# Cochrane

# Trusted evidence.

# Informed decisions.

# Library

# Better health.

# Cochrane Database of Systematic Reviews

# NCT03078803 (Continued)

- Antibiotic exposure within 30 days, probiotic exposure within 14 days, topical IBD therapy within 2 weeks, concurrent antibiotic therapy
- SES-CD score &lt; 5, severe CD HBI &gt; 25, or need for hospitalization
- Active perianal disease, abdominal abscess, extensive colonic resection, subtotal or total colectomy, ileostomy, colostomy, known fixed symptomatic stenosis or complex fistulae, upper CD
- Any need for surgical intervention (e.g. bowel resection within 3 months of enrollment)
- Presence of or treatment for Clostridioides difficile or other gastrointestinal pathogen including CMV within 28 days; chronic hepatitis B or C, or HIV infection
- History or evidence of adenomatous colonic polyps, colonic dysplasia, adhesions preventing colonoscopy to cecum
- Active substance abuse or psychiatric problems that may interfere with participation
- Pregnancy

# Interventions

# Experimental arm

First FMT at week 0 by colonoscopy + weekly FMT by oral capsules until week 7

# Control arm

First placebo (water) at week 0 by colonoscopy + weekly placebo by oral capsules until week 7

# Outcomes

# Primary outcomes

- Clinical and endoscopic remission at week 8 (HBI &lt; 5 and simple endoscopic score &lt; 5)

# Secondary outcomes

- Clinical response at week 8 (HBI reduction by 3 points)
- Clinical remission at week 8 (HBI &lt; 5)
- Endoscopic response at week 8 (SES-CD score reduction by 50%)
- Endoscopic remission at week 8 (SES-CD score &lt; 5)
- Quality of life 1 at week 8 (mean changes in Short IBDQ)
- Quality of life 2 at week 8 (mean changes in EQ-5D)
- Quality of life 3 at week 8 (mean changes in Work Productivity and Activity Impairment: Crohn's Disease Questionnaire)

# Starting date

# Contact information

# Notes

# NCT03110289

# Study name

Restoration of the microbiome through superdonor selection (RESTORE-UC)

# Methods

Multicenter RCT conducted in Belgium and the Netherlands

# Participants

# Inclusion criteria

- Age &gt; 18 years
- Current mild-to-moderate active UC (Endoscopic Mayo subscore 2–3, Total Mayo score 4–10)
- Concomitant UC therapy restricted to current treatment and at stable dose (not in induction phase)
- Use of methylprednisolone at maximum dose of 15 mg

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.